SFA 002
Alternative Names: SFA 002Latest Information Update: 24 Mar 2025
At a glance
- Originator SFA Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Interferon gamma inhibitors; Interleukin 12 inhibitors; Interleukin 17 inhibitors; Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
- Research Rheumatoid arthritis
Most Recent Events
- 11 Mar 2025 SFA Therapeutics plans a phase II/III trial for Plaque psoriasis (PO), in June 2025 (NCT06863493),
- 07 Mar 2025 Pharmacodynamics data from preclinical studies in Psoriasis presented at the American Academy of Dermatology annual Meeting 2025 (AAD-2025)
- 07 Mar 2025 Pharmacodynamics data from a preclinical study in plaque psoriasis released by SFA Therapeutics